In PerPrev-CID, we aim to advance our understanding of early disease progression in RA and IBD by investigating mechanisms, identifying biomarkers, and developing innovative, patient-centred outcome measures. We actively involve people living with or at risk of these conditions in the research process, supporting informed choices, and empower healthcare professionals with the knowledge and tools needed for more effective, individualised care.
About PerPrev-CID
The PerPrev-CID project aims to develop innovative tools for early diagnosis and personalised interventions in two chronic inflammatory diseases (CIDs), rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). By integrating biomarkers, clinical data, and digital health technologies, the project seeks to advance disease prediction and prevention, ultimately enhancing personalised healthcare and improving outcomes for people living with these conditions.
January 2025
Start date 
60 Months
Duration 
€ 13.5 Mil.
Funding 
15
Partners 
- Professor Philip Rosenstiel
Institute of Clinical Molecular Biology at UKSH and Kiel University
Partners
